Imagine lifesaving vascular access or replacement without requiring any cells or tissue from the patient. At Humacyte, this vision may become a reality thanks to our proprietary technology for developing human, tissue-based investigational products.
Our technology platform isolates and grows stable, off-the-shelf investigational human tissue replacements which, if approved, could be tailored to pre-designed clinical and commercial specifications for regenerative medicine, as well as for vascular and non-vascular surgery applications.
By growing these investigational tissues in vitro from banked vascular smooth muscle cells and then decellularizing them, we may be able to significantly reduce the risk of infection and tissue rejection. The result? An end product that can be ready on a hospital storage shelf for patients in need of vascular access or replacement.
Pre-clinical and clinical data suggests Humacyte human acellular vessels (HAV) may have the potential to extend patency with the possibility of some reduction in inflammation and some reduction in clotting.
Humacyte human acellular vessels may have the potential to be less immunogenic with the possibility of some reduction in foreign body response.
Humacyte human acellular vessels may have the potential to lower healthcare costs with reduced surgical interventions and more positive, long term, clinical outcomes.
Four products have already qualified for the regenerative medicine advanced therapy (RMAT) designation that provides extra interactions with the agency, and sooner. Jef Akst for The Scientist – The 21st Century Cures Act, approved by the US Congress and signed…Read More »
Humacyte is pleased to share that Laura Dryda, Staff Writer with Becker’s Hospital Review just published her recent list on “110 Women in Medtech to Know” which includes a brief excerpt on Humacyte Founder Dr. Laura Niklason and Humacyte CEO Carrie Cox….Read More »